 | | Vol. 9.40 – 20 October, 2021 |
| |
|
|
| The authors longitudinally profiled vaccine responses in SARS-CoV-2 naïve and recovered individuals for six months after vaccination.
[Science] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Investigators developed spike-deleted SARS-CoV-2 self-replicating RNAs using a yeast-based reverse genetics system.
[Science] |
|
|
|
| Scientists found that the effectiveness of BNT162b2 and ChAdOx1 against infections with symptoms or high viral burden was reduced with the B.1.617.2 variant compared to the B.1.1.7 variant.
[Nature Medicine] |
|
|
|
| Lung autopsy samples from 18 patients with fatal COVID-19, with symptom onset-to-death times ranging from 3 to 47 days, and antemortem plasma samples from six of these cases were evaluated using deep sequencing of SARS-CoV-2 RNA, multiplex plasma protein measurements, and pulmonary gene expression and imaging analyses.
[Science Translational Medicine] |
|
|
|
| Researchers performed mechanistic studies in mice to understand how the priming dose of an adenovirus-based SARS-CoV-2 vaccine affected long-term immunity to SARS-CoV-2.
[Science Immunology] |
|
|
|
| Investigators conducted a longitudinal study of infection-naïve and COVID-19 convalescent donors before vaccination and after their first and second vaccine doses, using a high-parameter CyTOF analysis to phenotype their SARS-CoV-2-specific T cells.
[eLife] |
|
|
|
| The authors compared humoral and cellular responses against SARS-CoV-2 variants of concern in subjects immunized with the DNA vaccine, INO-4800.
[npj Vaccines] |
|
|
|
| Three immunodominant linear B cell epitopes in the SARS-CoV-2 spike receptor-binding domain (RBD) were identified by immunoinformatics prediction, and confirmed by ELISA with sera from Macaca fascicularis vaccinated with a SARS-CoV-2 RBD subunit vaccine.
[Scientific Reports] |
| | MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| Using molecular modeling, scientists found DENV2 E protein mutations that induced dimerization at low concentrations and enhanced production yield by more than 50-fold.
[Science Advances] |
|
|
|
| Researchers showed that HIV-1 proviruses integrated in the first introns of signal transducer and activator of transcription 3 and lymphocyte-specific protein tyrosine kinase could play an important role in the development of T cell lymphomas.
[Science Advances] |
|
|
|
| The authors showed that mammalian target of rapamycin complex 2 was essential for the survival of experimental animals after ocular HSV-1 infection in vivo.
[Nature Communications] |
|
|
|
| Investigators demonstrated the successful production of DIPs harboring deletions in segments 1 and/or 3, using cell lines that co-expressed PB2 and PA.
[Scientific Reports] |
|
|
|
|
| An important challenge during the COVID-19 pandemic has been to understand asymptomatic disease and the extent to which this may be a source of transmission. Areas that need greater clarity include the extent to which asymptomatic disease leads to persistent symptoms, and the quality, quantity and durability of immune priming required to confer subsequent protection.
[Nature Reviews Immunology] |
|
|
|
| The authors discuss nonimmunological pathogenic mechanisms that converge on the ability of bacteria to control the mitochondrial compartment of host cells.
[Trends in Microbiology] |
|
|
|
|
| Gilead Sciences, Inc. announced the FDA approved a new low-dose tablet dosage form of Biktarvy® for pediatric patients weighing at least 14 kg to less than 25 kg who are virologically suppressed or new to antiretroviral therapy.
[Gilead Sciences, Inc.] |
|
|
|
| Moderna, Inc. confirmed that the FDA Vaccines and Related Biological Products Advisory Committee recommended that the FDA grant an Emergency Use Authorization for a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older; people aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 whose exposure to COVID-19 puts them at risk for COVID-19 complications or severe illness.
[Moderna, Inc.] |
|
|
|
| Merck announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of VAXNEUVANCE™ for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older.
[Merck (BusinessWire, Inc.)] |
|
|
|
|
| November 10 – 12, 2021
Virtual |
|
|
|
|
|
| | Helmholtz Zentrum München – Augsburg, Germany |
|
|
|
| | University of Pittsburgh Graduate School of Public Health – Pittsburgh, Pennsylvania, United States |
|
|
|
| | University of Cambridge – Cambridge, England, United Kingdom |
|
|
|
| | Colorado State University – Fort Collins, Colorado, United States |
|
|
|
| | Vanderbilt University Medical Center – Nashville, Tennessee, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
